A Phase II Neo-Adjuvant Study of Letrozole in Combination with Lapatinib in Post-Menopausal Patients with HER2-positive and Hormone Receptor-positive Operable Breast Cancer (SPORE).
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2012
At a glance
- Drugs Lapatinib; Letrozole
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Dec 2010 Actual end date (1 Dec 2010) added as reported by ClinicalTrials.gov.
- 01 Dec 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.